The requested URL /esi/auxiliary-nav.html was not found on this server.
Additionally, a 404 Not Found error was encountered while trying to use an ErrorDocument to handle the request.
March 12, 2019
Edited by Kara A. Specht; Elizabeth D. Ferrill
In University of Florida Research Foundation, Inc. v. General Electric Company, No. 18-1284 (Fed. Cir. Feb. 26, 2019), the Federal Circuit affirmed the district court’s grant of GE’s motion to dismiss UFRF’s allegations of infringement.
In 2017, UFRF sued GE alleging infringement of the ‘251 patent, which described a method and system for ‘integrat[ing] physiologic data from at least one bedside machine.” GE filed a motion to dismiss, arguing that the claims of the ‘251 patent were directed to ineligible subject matter under 35 U.S.C. § 101, which the district court granted.
On appeal, UFRF argued that the district court did not have subject matter jurisdiction to hear GE’s § 101 eligibility challenge because UFRF enjoyed sovereign immunity under the Eleventh Amendment. The Federal Circuit held that UFRF consented to federal court jurisdiction, thus waiving its Eleventh Amendment immunity, when it brought the infringement claim against GE. The Federal Circuit explained that the waiver of immunity extends not only to the cause of action but to any relevant defenses GE brought, including the §101 challenge.
After confirming subject matter jurisdiction on the §101 eligibility challenge, the Federal Circuit affirmed the district court’s finding that UFRF’s ‘251 patent was directed to an abstract idea.
Copyright © 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Webinar
Sanofi, Vanda, and GSK, a New Year Voyage through the Land of Induced Infringement
January 21, 2021
Webinar
Federal Circuit IP Blog
A New Application of an Abstract Idea Is Still Abstract: Court Affirms Dismissal Under § 101
January 21, 2021
Federal Circuit IP Blog
Disavowal of Infringement Case Eliminates Article III Standing for Appeal of IPR
January 13, 2021
Federal Circuit IP Blog
Federal Circuit Finds Preamble Limiting When It Supplies the Claim’s Structure
January 12, 2021
Prosecution First Blog
January 8, 2021
Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.